![]() |
Name |
Tajixanthone methanoate
|
Molecular Formula | C26H30O7 | |
IUPAC Name* |
(1R,2S)-1,11-dihydroxy-8-[(2S)-2-hydroxy-3-methoxy-3-methylbutyl]-5-methyl-2-prop-1-en-2-yl-2,3-dihydro-1H-pyrano[3,2-a]xanthen-12-one
|
|
SMILES |
CC1=CC2=C(C3=C1OC[C@@H]([C@H]3O)C(=C)C)C(=O)C4=C(C=CC(=C4O2)C[C@@H](C(C)(C)OC)O)O
|
|
InChI |
InChI=1S/C26H30O7/c1-12(2)15-11-32-24-13(3)9-17-20(21(24)22(15)29)23(30)19-16(27)8-7-14(25(19)33-17)10-18(28)26(4,5)31-6/h7-9,15,18,22,27-29H,1,10-11H2,2-6H3/t15-,18+,22-/m1/s1
|
|
InChIKey |
QWNQVPWHVUVFIF-FXCLAUTBSA-N
|
|
Synonyms |
tajixanthone methanoate; CHEMBL1079883
|
|
CAS | NA | |
PubChem CID | 46883486 | |
ChEMBL ID | CHEMBL1079883 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 454.5 | ALogp: | 4.1 |
HBD: | 3 | HBA: | 7 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 105.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 33 | QED Weighted: | 0.383 |
Caco-2 Permeability: | -4.879 | MDCK Permeability: | 0.00000997 |
Pgp-inhibitor: | 0.534 | Pgp-substrate: | 0.946 |
Human Intestinal Absorption (HIA): | 0.07 | 20% Bioavailability (F20%): | 0.005 |
30% Bioavailability (F30%): | 0.009 |
Blood-Brain-Barrier Penetration (BBB): | 0.052 | Plasma Protein Binding (PPB): | 87.11% |
Volume Distribution (VD): | 0.948 | Fu: | 10.31% |
CYP1A2-inhibitor: | 0.393 | CYP1A2-substrate: | 0.936 |
CYP2C19-inhibitor: | 0.058 | CYP2C19-substrate: | 0.286 |
CYP2C9-inhibitor: | 0.386 | CYP2C9-substrate: | 0.738 |
CYP2D6-inhibitor: | 0.256 | CYP2D6-substrate: | 0.292 |
CYP3A4-inhibitor: | 0.227 | CYP3A4-substrate: | 0.309 |
Clearance (CL): | 3.261 | Half-life (T1/2): | 0.113 |
hERG Blockers: | 0.018 | Human Hepatotoxicity (H-HT): | 0.515 |
Drug-inuced Liver Injury (DILI): | 0.808 | AMES Toxicity: | 0.657 |
Rat Oral Acute Toxicity: | 0.904 | Maximum Recommended Daily Dose: | 0.946 |
Skin Sensitization: | 0.471 | Carcinogencity: | 0.858 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.015 |
Respiratory Toxicity: | 0.53 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002651 | ![]() |
0.853 | D0Q0PR | ![]() |
0.261 | ||
ENC002623 | ![]() |
0.765 | D0F7CS | ![]() |
0.257 | ||
ENC002341 | ![]() |
0.710 | D06GCK | ![]() |
0.254 | ||
ENC002544 | ![]() |
0.664 | D0K8KX | ![]() |
0.252 | ||
ENC004145 | ![]() |
0.645 | D04UTT | ![]() |
0.246 | ||
ENC004314 | ![]() |
0.609 | D0O6KE | ![]() |
0.240 | ||
ENC002916 | ![]() |
0.598 | D0O1UZ | ![]() |
0.236 | ||
ENC006093 | ![]() |
0.598 | D04AIT | ![]() |
0.235 | ||
ENC004538 | ![]() |
0.537 | D02ZJI | ![]() |
0.229 | ||
ENC004537 | ![]() |
0.537 | D0K5CB | ![]() |
0.229 |